Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 2/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756096 | 0.80 | NR3C2 (0.61) | NR3C2SCN9A | |
| SCHEMBL754733 | 0.78 | PKM (0.50) | SLC9A1NR3C2CYP3A4 | |
| SCHEMBL754584 | 0.77 | NR3C2 (0.46) | SLC9A1NR3C2CYP3A4NFKB1PMP22 | |
| SCHEMBL756144 | 0.76 | NR3C2 (0.42) | SLC9A1NR3C2CYP3A4NFKB1PMP22 | |
| SCHEMBL753893 | 0.75 | NR3C2 (0.37) | SLC9A1NR3C2CYP3A4NFKB1PMP22 | |
| SCHEMBL756500 | 0.74 | SLC9A1 (0.36) | SLC9A1NR3C2CYP3A4NFKB1PMP22 | |
| SCHEMBL756030 | 0.74 | NR3C2 (0.47) | SLC9A1NR3C2CYP3A4NFKB1PMP22 | |
| SCHEMBL27756128 | 0.74 | — | — | |
| SCHEMBL14320744 | 0.73 | PDE3B (0.48) | SLC9A1NR3C2PDE3BPDE3AKRAS | |
| SCHEMBL759723 | 0.72 | NR3C2 (0.49) | SLC9A1NR3C2XIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188073-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-1984345-B9 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | IIJIMA TORU | 2011-10-13 | — | — | US | disclosed |
| EP-1984345-B1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7998956-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | SLC9A1 407/4885NR3C2 1/4885CYP3A4 398/4885 |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | NR3C2, MC2R, NR3C1 | SLC9A1 407/4885NR3C2 1/4885CYP3A4 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.